Diabetic ketoacidosis induced by single dose of pembrolizumab
Immune checkpoint inhibitors are a new class of anticancer drugs recently approved by the US Food and Drug Administration (FDA) for the treatment of various malignancies. Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein-1 (PD-1) receptor and blocks its i...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | article |
| Published: |
2019
|
| Online Access: | http://hdl.handle.net/10725/11295 https://doi.org/10.1016/j.ajem.2018.10.040 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S0735675718308544 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|